Administrative Data Misclassifi es and Fails to Identify Nephrotoxin-Associated Acute Kidney Injury in Hospitalized Children
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Acute kidney injury (AKI) is a potentially devastating event that places patients at increased risk of poor outcomes and is strongly linked to chronic kidney disease (CKD) in adults and children. [1] [2] [3] [4] The incidence of AKI is high and continues to increase, 2, [5] [6] [7] which may lead to increasing prevalence of CKD, which in turn could create long-term burdens on patients and health care systems. 8 In hospitalized children, recent studies have demonstrated that the cause of AKI is not primary renal disease, as was previously thought, but the result of a systemic illness or its treatment. 9 In noncritically ill hospitalized children, exposure www.hospitalpediatrics.org to nephrotoxic medications is among the most common causes of AKI and is associated with signifi cant morbidity, increased length of stay, and cost. [10] [11] [12] Recent studies have found AKI among noncritically ill patients to be associated with exposure to multiple nephrotoxins and to aminoglycoside antibiotics specifi cally. 11, 12 Accurate detection of AKI relies on serial measurements of serum creatinine (SCr) level or urine output over time. 13 However, noncritically ill pediatric patients are often not monitored for AKI and providers may miss an opportunity to prevent or diagnose AKI. 11, 12 The epidemiology of nephrotoxin-associated AKI on a large scale is therefore not well understood.
Administrative databases are a potentially useful means to better defi ne AKI epidemiology on a broad scale because of the large number of patients included.
14 Although administrative data capture some diagnoses well, [15] [16] [17] [18] for other diagnoses, administrative data are inherently inaccurate relative to clinical diagnoses. [19] [20] [21] [22] [23] Studying nephrotoxin-associated AKI in noncritically ill hospitalized children using administrative data has not been attempted. This is likely because of the absence of laboratory or patient urine output data, which are key to accurate diagnosis of AKI. The purpose of this study was to assess the sensitivity of administrative data to detect nephrotoxin-associated AKI among noncritically ill hospitalized patients. We hypothesized that, given infrequent monitoring of SCr, administrative data would not detect AKI effectively. We also hypothesized that if applied to a cohort in which monitoring was complete, the detection sensitivity would increase.
METHODS
Study Design
We conducted a single-center retrospective study in which administrative data were merged with laboratory values to allow direct comparison of AKI by discharge code and pediatricmodifi ed Risk, Injury, Failure, Loss, and End-Stage Renal Disease (pRIFLE) values, respectively.
Data Sources
SCr data were obtained from our hospital electronic health record. Data including demographics, all-patient refi ned diagnosis-related group (APR-DRG)-defi ned service line, 24 medications, and discharge coding for this study were obtained from the Pediatric Health Information System (PHIS). PHIS is an administrative database that contains inpatient, emergency department, ambulatory surgery, and observation data from 43 not-forprofi t, tertiary care pediatric hospitals in the United States. These hospitals are affi liated with the Children's Hospital Association (Overland Park, KS). Data quality and reliability are ensured through a joint effort between the Children's Hospital Association and participating hospitals. The data warehouse function for the PHIS database is managed by Truven Health Analytics (Ann Arbor, MI). For the purposes of external benchmarking, participating hospitals provide discharge/ encounter data including demographics, diagnoses, and procedures. Fortytwo of these hospitals also submit resource utilization data (eg, pharmaceuticals, imaging, and laboratory) into PHIS. Data are deidentifi ed at the time of data submission and subjected to a number of reliability and validity checks before being included in the database. PHIS allows a member hospital to reidentify patients so that medical record data can be linked to administrative data.
Comparison Cohort
We have previously described a cohort of nephrotoxin-exposed patients who were screened daily by SCr and tracked prospectively for development of AKI as part of a local quality improvement project. Details of the method of collection and database composition, compilation of the nephrotoxin list, and nephrotoxin exposure criteria are the subject of a separate report, which does not assess International Classifi cation of Diseases, Ninth Revision (ICD-9) codes. 25 As part of this quality improvement project, ∼99% of nephrotoxin-exposed patients had daily SCr measurement during their exposure. For the current study, patients with an admission and discharge date from June 1, 2011 through June 30, 2012 with a matching PHIS admission were included.
Exposure Defi nitions
Nephrotoxin exposure was defi ned as exposure to ≥3 nephrotoxins at once or ≥3 days of intravenous aminoglycoside antibiotic therapy. 11 Exposure to a dose of intravenous contrast material was considered 1 nephrotoxin exposure for the day of, and the day after the infusion. Adequate SCr screening was defi ned as 2 measurements obtained ≤96 hours apart during an admission. This time period was chosen because we knew that daily screening was unlikely 11, 12 and estimated that at least half of nephrotoxin-exposed patients would be screened every 96 hours (unpublished data). For the comparison cohort, exposure defi nitions were identical except for intravenous contrast material, for which exposure counted toward the day of and 6 days after the infusion, and adequate screening, which was defi ned as SCr measurement every day of exposure.
25
Outcome Defi nitions AKI was defi ned by ICD-9 code (584, 584.5, 584.6, 584.7, 584.8, 586, 584.9, and 593.9, 788.5) or by any of 3 strata (R, I, and F) of the SCr-based pRI-FLE.
11,12 AKI as determined by pRIFLE has been associated with poor outcomes in critically ill and noncritically ill children with AKI. 12, 13, 26, 27 Because nephrotoxin-associated AKI is usually nonoliguric in nature 28 and urine output data were unavailable, we did not use the pRIFLE urine output criteria. The pRIFLE-R stratus is considered injury by its 25% decrease in estimated creatinine clearance and was therefore included in this study. 13 The pRIFLE-L and E strata are long-term outcome measures of AKI and were not considered for this study.
Analysis
All analyses were performed by using SAS Software version 9.3 (SAS Institute Inc, Cary, NC). First, records for all admissions to CCHMC from January 1, 2009 through April 30, 2011, including medications administered, clinical service line, APR-DRG, underlying medical condition, and all discharge diagnoses were downloaded from the PHIS database. The following patients were excluded during the download: (1) those requiring intensive care because the etiology of AKI in these patients differs signifi cantly from noncritically ill patients;
(2) those with chronic kidney disease (defi ned as ICD-9 codes 188.×, 189.×, 209.64, 250.4×, 403, 404, 580.×, 581.×, 582.×, 583, 585.6, V42.0, and E879.1) to restrict our cohort to new-onset AKI; (3) those >18 years old; (4) those with admissions <24 hours in length (short-stay admissions) because SCr measurements from these admissions would be unlikely to identify an acute change from a baseline value.
To identify patients, deidentifi ed PHIS medical record numbers (MRNs) were converted to their original state. Next, the list of MRNs was used to download laboratory data from a separate, local database. The 2 datasets were merged using the combination of MRN, admission date, and discharge date as an identifi er of each unique admission and operational defi nitions described earlier were applied. Descriptive analysis was conducted in 3 groups: (1) the entire cohort, (2) all nephrotoxin-exposed patients, and (3) nephrotoxin-exposed patients screened adequately. Comparisons were made by group and not in pairwise fashion. Because of the increased statistical power provided by our large sample size, the P value for declaring statistical signifi cance in these group comparisons was set at .001 to reduce likelihood of a false-positive result. Change in SCr level was determined for pairs of values obtained for the same patient during the same admission no more than 96 hours apart. SCr values were ordered sequentially by date and each result was iteratively divided by the preceding result. For nephrotoxinexposed patients screened adequately, the sensitivity, specifi city, and positive and negative predictive values of ICD-9 codes for AKI were calculated in a standard 2 × 2 table using pRIFLE as the gold standard. www.hospitalpediatrics.org
Comparison Cohort
PHIS data were extracted, merged with existing AKI data from the project database, and subjected to the same exclusion criteria described above. Descriptive analysis was conducted as described earlier. Sensitivity, specifi city, and positive and negative predictive values were calculated in a standard 2 × 2 table using pRIFLE as the gold standard.
Human Subject Protection
Our institutional review board reviewed the project and considered it to be excluded from human subjects research. Informed consent beyond the standard consent for treatment of all inpatients was not required.
RESULTS
Patient Population
Among the 38 410 patients discharged from our hospital during the study period, there were 28 753 patients who met inclusion criteria. Of these, 1472 patients were nephrotoxin-exposed (5.1%), 747 (50.7%) of whom had adequate SCr screening (Fig 1) .
Demographics of nephrotoxin-exposed versus non-nephrotoxin-exposed patients are depicted in Table 1 . Patients with nephrotoxin exposure had signifi cantly longer lengths of stay and were exposed to a higher number of medications than those without nephrotoxin exposure. Nephrotoxinexposed patients were more likely to carry commercial insurance and unexposed patients more likely to carry Medicaid. Nephrotoxin-exposed patients had a higher proportion of white and Asian patients and lower proportions of American Indian and African American patients than unexposed patients. Exposed patients were sig nificantly more likely to have received care from cancer care and hematology, cardiac care, digestive disease, infectious disease, neonatal care, neuroscience, and solid organ or bone marrow transplant services, whereas unexposed patients were more likely to have received care from other medicine, orthopedics, and other surgery services. Table 2 depicts the demographics of ade quately screened (middle column) versus inadequately screened nephrotoxin-exposed patients (left col umn) and patients from the com parison cohort (right column). Com pared with inadequately screened patients, ad e quately screened nephrotoxin-exposed patients were younger; exposed to more medications; had a longer length of stay; were more likely to receive services through cancer care and hematology, infectious disease, and organ or bone marrow transplant services; and were more likely to use a form of insurance or payment other than commercial or self-pay. Race was not different between adequately and *P < .001 in comparison of inadequately screened nephrotoxin-exposed to adequately screened nephrotoxin-exposed subjects. **P < .001 in comparison of adequately screened nephrotoxin-exposed subjects to comparison cohort.
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Using discharge code, AKI was present in 26 (10.0%) of the same group. Sensitivity of nephrotoxin-associated AKI diagnosis by discharge code compared with pRIFLE criteria was 21.4% (95% CI 11.8-31.0), and specifi city was 94.2% (95% CI 90.1-97.5). The positive predictive value of nephrotoxinassociated AKI by discharge coding was 57.7% (95% CI 38.7-76.7), and the negative predictive value was 76.6% (95% CI 71.2-82.0). Results of the analysis are depicted in Fig 2B. 
DISCUSSION
The results of this study support the use of SCr-based criteria, such as pRIFLE, rather than reliance on administrative coding data to estimate the incidence of nephrotoxin-associated AKI in the hospitalized noncritically ill pediatric population. However, in the absence of widespread adequate screening by serial SCr measurement or accurate re porting of urine output, pRIFLE can not be applied reliably and thus may still underestimate nephrotoxin-associated AKI incidence. Our study found 58% more patients with nephrotoxin-associated AKI when applying pRIFLE criteria compared with ICD-9 criteria. The additional cases identifi ed were not due to pRIFLE identifying only less severe cases and ICD-9 codes identifying only the most severe. For the study cohort, when separated by pRIFLE severity class, the sensitivity of detection increased but not considerably as severity of injury increased (Data Not Shown). Thus, pRIFLE criteria appear superior to ICD-9 code no matter how severe the AKI.
The ideal interval for screening for nephrotoxin-associated AKI in exposed patients is unknown. Daily screening, as was conducted in the comparison cohort, 25 detected 2.5 times more AKI than screening within 96 hours, as was allowed in the study cohort (28.0% vs 11.0%). Without frequent monitoring of SCr in nephrotoxin-exposed patients, AKI may go undetected. However, the long-term effects of nephrotoxinassociated AKI are currently not well known. 9 The justifi cation of frequent, costly SCr measurements is therefore diffi cult. Given the potential damage that is known from studies of AKI in adult and pediatric patients who did not examine nephrotoxin exposure specifi cally, 4, 29, 30 we believe more frequent measurement is indicated.
Finding that nephrotoxin-exposed patients had longer lengths of stay and total number of medications administered compared with non-nephrotoxinexposed patients was not surprising. It is likely that with increased time spent admitted to the hospital, more medications will be administered, and the likelihood of nephrotoxin exposure will increase. This also may be confounding by indication, where sicker patients a priori receive more medications and stay longer. Both of these concepts are consistent with our fi nding of nephrotoxin-exposed patients predominantly associated with APR-DRG service lines where one would expect to fi nd patients with malignancy, bone marrow transplant, multivisceral and liver transplant, and cystic fi brosis. We have observed these patient populations to be overrepresented among nephrotoxin-exposed patients, likely due to prolonged hospitalization and frequent use of nephrotoxins for treatment. 25 Likewise, it is easy to imagine cardiac care (surgical, transplant) and neonatal (premature infants on multiple antibiotics) services among this cohort of patients. It is less clear why nephrotoxin-exposed patients had different insurance coverage and race. This is less likely to indicate an association of socioeconomic status or race with nephrotoxin exposure and more likely to be a result of the specifi c patient population cared for at our institution. Many patients receiving care for the most complex conditions come from outside the immediate hospital catchment area including a portion from outside the United States. Thus, these patients may skew the racial and insurance status distributions for the exposed population. The predominance of transplant and respiratory service patients in the comparison cohort may have increased the risk of AKI compared with the adequately screened cohort. However, fewer patients associated with an infectious disease, digestive disease, and cancer APR-DRG service line may have balanced some of the risk between the groups. Thus, we felt the nephrotoxin-exposed adequately screened and comparison cohorts could be compared directly.
Administrative data have many advantages for epidemiologic study in hospitalized pediatric populations, including generating large multicenter cohorts of patients to examine exposures and outcomes over time. 14 However, administrative data are also subject to limitations, such as an inherent inaccuracy of ICD-9 codes relative to clinical diagnoses. [19] [20] [21] [22] [23] Administrative data has been used to identify CKD and AKI in adult populations. For CKD, sensitivities showed a high degree of variation, with a median of 41%. AKI sensitivities were considered poor, with a median of 21%. 31 The ICD-9 codes used in our study did not match any of the sets used in the aforementioned studies, which were all performed in adults, making direct comparison diffi cult. Nonetheless, our results are consistent with previous analyses. The disagreement between ICD-9 codes and clinical diagnoses is thought to be multifactorial, including the former being generated by professional billing staff, who are limited in the codes they can use by the specifi c words used in the clinical notes. 23 Given these limitations, we were not surprised to fi nd that use of ICD-9 codes alone identifi ed only 19 of the 82 (23.2%) patients with nephrotoxin-associated AKI by pRIFLE criteria (Fig 2A) .
For the comparison cohort, we assumed our near complete case identifi cation and ensured documentation of AKI in the medical record would yield more accurate billing code data. The similarly low sensitivity in our comparison cohort (Fig 2B) was therefore unexpected. This is of particular signifi cance given the reliance on administrative data for public reporting, national benchmark and performance data, and Medicare reimbursement decisions. [32] [33] [34] Future study is needed to fully understand the apparent disconnect between chart documentation and administrative data to inform population-based estimates of burden and cost of nephrotoxin-associated AKI in the pediatric population.
